ArticleChemMedChem2026
Design, Synthesis, and Evaluation of New Polyhydroxylated Bis-Chalcones as Potential COX-2 Selective Inhibitors.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The challenges of direct Claisen-Schmidt condensation in the synthesis of polyhydroxylated bischalcones: experimental results supported by DFT calculations.Beilstein journal of organic chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Selective inhibition of COX-2 is considered one of the best strategies for treating chronic inflammatory diseases. However, the currently available options still have significant side effects due to exacerbated selectivity. Bis-chalcone derivatives have shown promising anti-inflammatory properties with reduced side effects. In this study, a family of polyhydroxylated bis-chalcones was synthesized and tested in vitro for their ability to inhibit human COX-2 and COX-1 and to assess selectivity. To further understand their mechanism of action, inhibitory kinetic analysis and in silico molecular docking calculations were performed. The results showed that bis-chalcone 31, with hydroxy groups at positions 3' and 4' of the B rings and three hydroxy groups at the center, was the most active. It was recognized as a mixed-type inhibitor with balanced selectivity. With molecular docking, it was observed that this substitution pattern provided bis-chalcone 31 with additional bulk that hindered its access to the active pocket of COX-1 over COX-2. Also, compound 31 establishes additional hydrogen bonds within the COX-2 pocket that bis-chalcone 30 did not, therefore explaining the selectivity and superior potency of bis-chalcone 31. In conclusion, bis-chalcone 31 with multiple hydroxy groups in its structure shows promising properties for the design of new COX-2 selective inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.